The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
Does your merger trigger Canada’s “rebuttable structural presumption”?
This article, authored by CRA’s Ian Cass, provides a brief reference guide along with a visual tool to help assess whether a merger meets the prescribed market...